Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema cardiovascular safety trial in obesity with established cardiovascular disease
2021-005855-35Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of cagrilintide and semaglutide in obesity and atherosclerotic disease (2 arms), sponsored by Novo Nordisk. Primary endpoint: Time to first occurrence of MACE. Started Nov 2022; status: active.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesityatherosclerotic disease
Beyond the preview
Go deeper on 2021-005855-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005855-35.